Selegiline and rasagiline: Twins or distant cousins?

Consultant Pharmacist

Volumn 26, Issue 1, 2011, Pages 48-51

  Knudsen Gerber, Dawn S ^a  

^a MIDWESTERN UNIVERSITY   (United States)

Author keywords

MAO A inhibitor; MAO B inhibitor; Parkinson's disease; Rasagiline; Selegiline

Indexed keywords

AMINE OXIDASE (FLAVIN CONTAINING); AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME A; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; AMPHETAMINE; BENZATROPINE; BROMOCRIPTINE MESILATE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; LEVODOPA; METHAMPHETAMINE; MONOAMINE OXIDASE INHIBITOR; RASAGILINE; SELEGILINE; TYRAMINE; INDAN DERIVATIVE;

ABNORMAL DREAMING; BLOOD PRESSURE; CLINICAL DECISION MAKING; DRUG APPROVAL; DRUG LABELING; DRUG METABOLISM; DRUG SAFETY; DYSKINESIA; ENZYME INHIBITION; HEART DISEASE; HUMAN; MENTAL DISEASE; MOTOR DYSFUNCTION; NEUROPROTECTION; PARKINSON DISEASE; PARKINSONISM; PHARMACIST; QUALITY OF LIFE; REVIEW; DRUG INACTIVATION; METABOLISM; PHYSIOLOGY;

HUMANS; INACTIVATION, METABOLIC; INDANS; MONOAMINE OXIDASE INHIBITORS; PARKINSON DISEASE; SELEGILINE;

EID: 80051562700     PISSN: 08885109     EISSN: None     Source Type: Journal    
DOI: 10.4140/TCP.n.2011.48     Document Type: Review

References (22)

1. DiPiro JT, Talbert RL, Yee GC et al. Pharmacotherapy: a pathophysiologic approach. 7th ed. New York, NY: McGraw-Hill Medical; 2008:chap. 61.
2. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol 2002;59:1937-43.
3. Rascol O, Brooks DJ, Melamed E et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomized, double-blind, parallel-group trial. Lancet 2005;365:914-6.
4. Parkinson Study Group. DATATOP: a multi-center controlled clinical trial in early Parkinson's disease. Arch Neurol 1989;46:1052-60.
5. Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. Arch Neurol 2005;62:241-8.
6. Olanow CW, Hauser R, Jankovic J et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord 2008;23:2194-201.
7. U.S. Food and Drug Administration. Approved Drug Products- Eldepryl. Available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm? fuseaction=Search.DrugDetails. Accessed July 31, 2009.
8. U.S. Food and Drug Administration. Approved Drug Products- Azilect. Available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm? fuseaction=Search.DrugDetails. Accessed July 31, 2009.
9. Young D. Drug innovation on the decline. February 1, 2007. Available at http://www.ashp.org/import/news/HealthSystem PharmacyNews/newsarticle.aspx?id= 2416. Accessed August 12, 2009.
10. U.S. Food and Drug Administration. Approved Drug Products- Sinemet. Available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm? fuseaction=Search.DrugDetails. Accessed July 31, 2009.
11. U.S. Food and Drug Administration. Approved Drug Products- Requip. Available at http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm? fuseaction=Search.DrugDetails. Accessed July 31, 2009.
12. Chen JJ, Lew MF, Siderowf A. Treatment strategies and quality-of- care indicators for patients with Parkinson's disease. J Manag Care Pharm 2009;15 3 Suppl:1-21.
13. Lewitt PA. Levodopa for the treatment of Parkinson's disease. N Engl J Med 2008;359:2468-76.
14. Eldepryl prescribing information. 1997. Available at http://www.l- deprenyl.com/prescribe/index.html. Accessed July 31, 2009.
15. Helms RA, Quan DJ, Herfindal ET et al. Textbook of Therapeutics: Drug and Disease Management. 8th ed. New York, NY: Lippincott Williams & Wilkins; 2006:1655,1657.
16. Parkinson Study Group. Tyramine challenge to assess the safety of rasagiline monotherapy in a placebo-controlled multicenter trial for early Parkinson's disease (the TEMPO study). Neurology 2001;56 Suppl 3:345. Abstract.
17. Marcaida JA. Rasagiline does not promote tyramine pressor responses. Mov Disord 2005;20 Suppl 10:133. Abstract.
18. Azilect EMEA (European) prescribing information. 2005.
19. Chen JJ, Ly A. Rasagiline: a second-generation monoamine oxidase type-B inhibitor for the treatment of Parkinson's disease. Am J Health Syst Pharm 2006;63:915-28. (Pubitemid 43764968)
20. Fernandez HH, Chen JJ. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease. Clin Neuropharmacol 2007;30:150-68. (Pubitemid 46871865)
21. Bar Am O, Amit T, Youdim MB. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett 2004;355:169-72. (Pubitemid 38368730)
22. Lewitt PA. MAO-B inhibitor know-how: back to the pharm. Neurology 2009;72:1352-7.